AIM ImmunoTech shares are trading higher after the company reported year-end data from the ongoing Phase 2 clinical study evaluating AIM's drug Ampligen combined with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi for the treatment of pancreatic cancer.